0551 Telemedicine Motivational Enhancement in Heart Failure and Sleep Apnea Randomized Clinical Trial
Cinthya Pena Orbea,James Bena,Elieen Hsich,Michelle Drerup,Rami Khayat,Reena Mehra
DOI: https://doi.org/10.1093/sleep/zsae067.0551
IF: 6.313
2024-04-20
SLEEP
Abstract:Abstract Introduction Despite evidence suggesting that Positive Airway Pressure (PAP) in patients with Acute Decompensated Heart Failure (ADHF) with Obstructive Sleep Apnea (OSA) confers improvement of cardiovascular outcomes, PAP adherence remains exceedingly low. We hypothesized that motivational enhancement (ME) via a telemedicine intensive approach improves PAP adherence post-discharge in hospitalized patients with ADHF and OSA Methods Telemedicine Intensive Motivational Enhancement (TIME) (NCT04752462) is an ongoing randomized clinical trial designed to investigate telemedicine ME effect on post-discharge PAP adherence, rehospitalizations, and patient-reported outcomes compared to standard of care at 3 and 6 months in patients admitted with ADHF and in-hospital OSA diagnosis (respiratory event index, REI>5). We describe baseline characteristics of 56 patients currently enrolled. Unadjusted and adjusted linear models were used to describe associations of OSA measures (Respiratory Event Index, REI and percentage of recording time< 90%SaO2,T90) with Kansas City Cardiomyopathy Score(KCCQ). Adjusted models included age, sex, race, and body mass index(BMI). Results Since April 2021, 5,742 patients were screened and of these, 3,822 had an admission diagnosis of ADHF, of which 343 underwent in-hospital portable sleep testing. Of these, patients were excluded for the following reasons: central predominant apneas (CA >50% of total REI) 31.5%(n=108), sleep-related hypoxemia 18.7%(n=64), negative for OSA 20.1%(n=69), declined PAP therapy 10.5%(n=36) or declined to participate in the clinical trial 2.9(n=10). Characteristics of the 56 participants currently enrolled are:age:60±14 years, 38% women, 45%black race, BMI of 35±8, left ventricular ejection fraction:40±16%, REI:26±14 and T90:19±17% and Epworth Sleepiness Scale:6[IQR, 3-10]. Comorbidities were hypertension 77%, atrial fibrillation 34%, valvular disease 21%, myocardial infarction 20%, and diabetes 39%. Self-reported health status at baseline was poor with a KCCQ score of 38±26. In adjusted analyses, for each unit increase of REI and T90, the overall KCCQ scores were associated with non-significant reduction by -0.29 (95% CI:-0.89,0.31, p=0.34) and -0.19(95%CI: -0.73,0.35,p=0.49) points respectively. Conclusion The TIME trial is designed to elucidate the effect of ME through telemedicine on PAP adherence and patient outcomes post-discharge in patients with ADHF and OSA. Directionally increased OSA severity was related to lower KCCQ scores, as expected, in OSA and ADHF, however, these relationships were not significant. Support (if any) AASM Foundation
neurosciences,clinical neurology